Literature DB >> 3358892

Biliary excretion of antipyrine and its metabolites after cholecystectomy.

H Mönig, J Wilhelmy, S John, E E Ohnhaus.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3358892      PMCID: PMC1386487          DOI: 10.1111/j.1365-2125.1988.tb03304.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


× No keyword cloud information.
  6 in total

1.  The antipyrine test in clinical pharmacology: conceptions and misconceptions.

Authors:  E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

2.  Studies on the different metabolic pathways of antipyrine in man. I. Oral administration of 250, 500 and 1000 mg to healthy volunteers.

Authors:  M Danhof; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1979-12       Impact factor: 4.335

3.  Differential effects of enzyme induction on antipyrine metabolite formation.

Authors:  M Danhof; R M Verbeek; C J van Boxtel; J K Boeijinga; D D Breimer
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

4.  HPLC determination of antipyrine metabolites.

Authors:  M Eichelbaum; B Sonntag; H J Dengler
Journal:  Pharmacology       Date:  1981       Impact factor: 2.547

5.  The absence of significant biliary excretion of antipyrine or its metabolites in humans.

Authors:  P S Wissel; A Kappas
Journal:  Clin Pharmacol Ther       Date:  1987-01       Impact factor: 6.875

6.  Antipyrine metabolism in relation to polymorphic oxidations of sparteine and debrisoquine.

Authors:  M Eichelbaum; L Bertilsson; J Säwe
Journal:  Br J Clin Pharmacol       Date:  1983-03       Impact factor: 4.335

  6 in total
  2 in total

Review 1.  Quantifying hepatic function in the presence of liver disease with phenazone (antipyrine) and its metabolites.

Authors:  J V St Peter; W M Awni
Journal:  Clin Pharmacokinet       Date:  1991-01       Impact factor: 6.447

2.  The pharmacokinetics of antipyrine and three of its metabolites in the rabbit: intravenous administration of pure metabolites.

Authors:  J V St Peter; Y Abul-Hajj; W M Awni
Journal:  Pharm Res       Date:  1991-12       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.